Bristol Pravachol/Aspirin Co-Package Not Precedent For Combo Submissions
Executive Summary
Bristol-Myers Squibb's Pravachol/aspirin combination should not be viewed as a precedent for approval of other combination products, FDA's Cardiovascular & Renal Drugs Advisory Committee members suggested July 18